home / stock / adms / adms news


ADMS News and Press, Adamas Pharmaceuticals Inc. From 07/22/21

Stock Information

Company Name: Adamas Pharmaceuticals Inc.
Stock Symbol: ADMS
Market: NASDAQ
Website: adamaspharma.com

Menu

ADMS ADMS Quote ADMS Short ADMS News ADMS Articles ADMS Message Board
Get ADMS Alerts

News, Short Squeeze, Breakout and More Instantly...

ADMS - Adamas secures new patents for Gocovri and ADS-4101

Adamas Pharmaceuticals ([[ADMS]]) announces the issuance of two patents covering Gocovri (amantadine) extended-release capsules: U.S. Patent No. 11,065,213 issued on July 20, 2021, and U.S. Patent No. 11,077,073, projected to issue on August 3, 2021.These two patents are the first issued...

ADMS - Adamas Announces Issuance of New Patents for GOCOVRI and ADS-4101

-Drug-product and method-of-use patents strengthen and diversify GOCOVRI’s long-term patent portfolio- -Issuance of ADS-4101 patent in Japan for partial onset seizures in patients with epilepsy strengthens partnering opportunity- Adamas Pharmaceuticals, Inc. (...

ADMS - Adamas to Present at Upcoming William Blair Biotech Focus Conference

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at ...

ADMS - Adamas Pharmaceuticals: Share Price Range-Bound Despite Steady Revenue Growth

Adamas Pharmaceuticals reported their Q1 earnings with a slight beat on EPS and a slight miss on revenue. GOCOVRI continues to report impressive growth despite a lackluster launch. Despite the commercial progress, the ADMS share price remains suppressed. It looks as if the Street is w...

ADMS - Adamas to Present at Upcoming SVB Leerink CNS Forum

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the company will present “What’s Happening in Parkinson’s Dise...

ADMS - Debate Concerning Biogens Alzheimers Drug Approval

Biogen’s Alzheimer drug Aducanumab was approve amidst much debate. The Food and Drug Administration (FDA) grants accelerated approvals for drugs to treat serious illnesses for which there are no known, or very few, treatments. Was the drug to be marketed as Aduhelm incorrectly made avai...

ADMS - Debate Concerning Biogen's Alzheimer's Drug Approval

Biogen’s Alzheimer drug Aducanumab was approve amidst much debate. The Food and Drug Administration (FDA) grants accelerated approvals for drugs to treat serious illnesses for which there are no known, or very few, treatments. Was the drug to be marketed as Aduhelm incorrectly made avai...

ADMS - New Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson's Disease

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the publication of a new data analysis titled, “Effects of GOCOVRI® (ama...

ADMS - Adamas to Present at Upcoming June Conferences

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the organization will be participating in two upcoming June conferences: Chri...

ADMS - The Autism Spectrum Disorders (ASD) Market Is Projected To Reach $4.53 Billion By 2026

Palm Beach, FL – May 12, 2021 – Autism spectrum disorder (ASD) represents a group of neurodevelopmental disorders or disabilities; it is a heritable and a polygenic disorder. Autism spectrum disorder is lifelong and typically emerges during early childhood. Children show ASD-r...

Previous 10 Next 10